Evotec signs ion channel hit agreement with Almirall
To identify small molecule modulators of ion channel target involved in respiratory diseases
Evotec has entered into a collaboration with Spanish company Almirall to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.
Evotec will apply its in-depth electrophysiology and ion channel pharmacology expertise, as well as its state-of-the-art screening platform, for the identification and validation of novel modulators of the selected ion channel.
Evotec has a unique assay development and screening platform, built around proprietary and the latest commercial technologies, providing a flexible and high quality approach to lead identification for ion channels and other target classes.
‘We are proud to have been selected by Almirall for this important project,’ said Dr Mario Polywka, coo of Evotec. ‘We have invested significantly in our ion channel and electrophysiology platform and scientists in recent years, and this programme is further validation of the value we can bring to our partners. We look forward to collaborating with and supporting Almirall in their quest to find novel treatments to address respiratory diseases.’
No financial details were disclosed.
